Should I buy or sell Trevi Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares. View TRVI analyst ratings or view top-rated stocks .

What is Trevi Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12 month price objectives for Trevi Therapeutics' shares. Their TRVI share price targets range from $8.00 to $9.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 218.4% from the stock's current price. View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts .

How have TRVI shares performed in 2024?

Trevi Therapeutics' stock was trading at $1.34 at the start of the year. Since then, TRVI stock has increased by 99.3% and is now trading at $2.67. View the best growth stocks for 2024 here .

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TRVI earnings forecast .

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its earnings results on Wednesday, March, 20th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02.

What ETF holds Trevi Therapeutics' stock?

Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN) , Diffusion Pharmaceuticals (DFFN) , Fulcrum Therapeutics (FULC) , Genocea Biosciences (GNCA) , Marker Therapeutics (MRKR) , VYNE Therapeutics (VYNE) , Akero Therapeutics (AKRO) , Aldeyra Therapeutics (ALDX) , AzurRx BioPharma (AZRX) and Chimerix (CMRX) .

When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free TRVI Stock Alerts

$2.67

-0.14 (-4.98%)

(As of 03:53 PM ET)

Compare

Today's Range: $2.65
▼
$2.83
50-Day Range: $1.46
▼
$3.70
52-Week Range: $0.97
▼
$4.00

Volume: 93,611 shs
Average Volume: 284,658 shs
Market Capitalization: $184.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Trevi Therapeutics alerts:

Trevi Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 218.4% Upside
$8.50 Price Target
Short Interest: Healthy
1.51% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.39) to ($0.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

Medical Sector

425th out of 930 stocks

Pharmaceutical Preparations Industry

193rd out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Trevi Therapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.51% of the outstanding shares of Trevi Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Trevi Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trevi Therapeutics has recently decreased by 2.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Trevi Therapeutics does not currently pay a dividend.
Dividend Growth
Trevi Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRVI.

2.5

News and Social Media Coverage

News Sentiment
Trevi Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Trevi Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
2 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.46% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.39) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevi Therapeutics is -9.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevi Therapeutics is -9.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevi Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRVI Stock News Headlines

April 10, 2024 | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from Needham & Company LLC

April 9, 2024 | finance.yahoo.com

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

April 9, 2024 | prnewswire.com

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

April 4, 2024 | uk.investing.com

Trevi Therapeutics appoints new VP for clinical development

April 4, 2024 | prnewswire.com

Trevi Therapeutics to Participate in Upcoming April Events

April 2, 2024 | finance.yahoo.com

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

March 29, 2024 | msn.com

Tourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to it

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

March 28, 2024 | msn.com

Trevi Italian Restaurant at Forum Shops unexpectedly closes

March 27, 2024 | msn.com

Prominent Trevi Italian Restaurant Abruptly Closes at the Forum Shops

March 21, 2024 | insidermonkey.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

March 21, 2024 | finanznachrichten.de

Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

March 20, 2024 | benzinga.com

Trevi Therapeutics: Q4 Earnings Insights

March 20, 2024 | msn.com

TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023

March 20, 2024 | finance.yahoo.com

Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials

March 17, 2024 | msn.com

Gloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossa

March 16, 2024 | msn.com

Gloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossa

March 13, 2024 | finance.yahoo.com

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

March 7, 2024 | msn.com

One million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?

February 29, 2024 | finance.yahoo.com

private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week

February 28, 2024 | finance.yahoo.com

Trevi Therapeutics to Participate in Upcoming March Events

February 28, 2024 | prnewswire.com

Trevi Therapeutics to Participate in Upcoming March Events

February 24, 2024 | thestreet.com

Trevi Therapeutics Inc.

February 22, 2024 | finance.yahoo.com

TRVI Mar 2024 2.000 call

February 18, 2024 | finance.yahoo.com

TRVI Mar 2024 3.000 call

February 6, 2024 | finance.yahoo.com

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

See More Headlines

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TRVI
CUSIP: N/A
CIK: 1563880
Web: www.trevitherapeutics.com
Phone: (203) 304-2499
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $9.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +218.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.51%
Return on Assets: -28.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.03
Quick Ratio: 15.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.29 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 68,960,000
Free Float: 50,024,000
Market Cap: $184.12 million
Optionable: Optionable
Beta: 0.86

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Ms. Jennifer L. Good (Age 59)
Co-Founder, CEO, President & Director
Comp: $781.85k
Dr. Thomas R. Sciascia M.D. (Age 71)
Co-Founder & Chief Science Officer
Comp: $530.48k
Dr. David J. Clark A.F.P.M. (Age 59)
M.D., M.R.C.P., Chief Medical Officer
Comp: $325.39k
Ms. Lisa Delfini (Age 54)
Chief Financial Officer
Mr. Christopher Galletta (Age 46)
Controller & Chief Accounting Officer
Katie McManus
Communications Manager
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Ms. Danine Summers (Age 66)
Vice President of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings or view top-rated stocks.
What is Trevi Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 12 month price objectives for Trevi Therapeutics' shares. Their TRVI share price targets range from $8.00 to $9.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 218.4% from the stock's current price.
View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts.
How have TRVI shares performed in 2024?: Trevi Therapeutics' stock was trading at $1.34 at the start of the year. Since then, TRVI stock has increased by 99.3% and is now trading at $2.67.
View the best growth stocks for 2024 here.
When is Trevi Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TRVI earnings forecast.
How were Trevi Therapeutics' earnings last quarter?: Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its earnings results on Wednesday, March, 20th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02.

What ETF holds Trevi Therapeutics' stock?: Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.58% of its portfolio.
What other stocks do shareholders of Trevi Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).
When did Trevi Therapeutics IPO?: Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.
How do I buy shares of Trevi Therapeutics?: Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial